Graves' Ophthalmopathy Clinical Trial
Verified date | June 2005 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Department of Health |
Study type | Observational |
The exact mechanism of the pathogenesis of Graves’ ophthalmopathy is still unknown.
Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two
prominent changes. In the past year, we had investigated the morphological features of the
Müller muscle in patients with thyroid lid retraction using the special stain and
immunohistochemistry. In our findings, the smooth muscle cells, in the diseased group, were
replaced by variable adipose and fibrosis tissues.
In recent years, TSHR, has been verified to express in orbital connective tissue and
extra-ocular muscle. From functional studies and an increase in adipogenesis in cultured
fibroblasts with expression of TSHR protein, the role not only the target but effector cells
in orbital fibroblasts were validated. Quantitative RT-PCR may help to differentiate whether
a less extent of expression at the end stage or low protein amount to be detected.
In recent years, the diverse phenotypes of orbital fibroblasts, with regard to expression of
Thy-1 protein or not, had been reported from several studies, the investigators believed
heterogeneity in orbital fibroblast may determine the clinical presentation of
Graves’ophthalmopathy. We also are curious to know if the phenotypic heterogeneity of the
fibroblasts in the ocular adnexal and orbital tissues correlates to distinct morphological
features of adipogenesis and fibrosis.
Moreover, increased CD40 expression in skin fibroblasts were noted from patients with
systemic sclerosis. Expression of IGF-I and IGF-IR seemed to be up-regulated in processes of
several fibrotic diseases. A nuclear transcription factor, PPAR-γ, has been verified to have
a close relationship with adipogenesis. We hypothesize that some immunological processes
involve the ocular adnexal and orbital tissues, which result in various ophthalmological
manifestations.
The purpose of this study is to investigate the different stage of the ocular adnexal and
orbital tissues to identify the pathogenesis of Graves' ophthalmopathy by frozen sections
with Immunohistochemistry, mRNA expression of TSH receptor, PPAR-γ, IGF-1R, and IGF-1 and
different cytokines using quantitative RT-PCR and flow cytometry at the acute and stable
stage in GO.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria:patients with Graves ophthalmopathy - Exclusion Criteria:no |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Taiwan | Shu Lang Liao | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02059655 -
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
|
Phase 4 | |
Completed |
NCT02721992 -
Graves' Orbitopathy and Hypercholesterolemia
|
N/A | |
Recruiting |
NCT02290704 -
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People
|
N/A | |
Recruiting |
NCT01969019 -
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT01056419 -
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
|
Phase 4 | |
Completed |
NCT00697528 -
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
|
N/A | |
Completed |
NCT00430547 -
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
|
N/A | |
Completed |
NCT03922321 -
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
|
Phase 2 |